Market evolution: Sulphonamides (CN 29359090) — 2015–2025

Introduction

This report analyses the trade dynamics of sulphonamides under Combined Nomenclature code 29359090 for the European Union over the period 2017–2025 (the window for which complete annual data is available). Sulphonamides are a broad class of organic chemicals used primarily as intermediates in pharmaceutical manufacturing (notably antibiotics) and, to a lesser extent, in agrochemicals. The EU's position in this market has undergone a dramatic structural transformation over the period examined: the bloc has shifted from being a net exporter with a comfortable trade surplus to a deeply import-dependent market running a large deficit. This report identifies and explains three overarching dynamics that define this evolution.

1. From Surplus to Deficit: A Structural Reversal of the EU Trade Balance

The single most striking feature of the EU's sulphonamide trade over 2017–2025 is the collapse of its trade balance, moving from a healthy surplus to a pronounced deficit.

The trade surplus eroded rapidly after 2021

In 2017, the EU recorded a trade balance of +€715 million. By 2025, this had reversed to −€1,873 million, a swing of approximately €2.6 billion (−362%). The reversal was not gradual but accelerated, with the balance turning negative around 2022–2023 as import growth vastly outpaced exports.

Export values fell while volumes barely grew

EU export volumes were essentially flat, but the average unit price of exports fell by over a third. This suggests either a shift in the product mix toward lower-value sulphonamides or intensifying price competition from global rivals, compressing margins for EU producers.

Import values doubled on rising volumes and prices

Import volumes grew by nearly 29%, but import values more than doubled because unit import prices rose by 56%. This dual effect — more tonnes and higher prices per tonne — drove the surge in the EU's import bill.

Domestic production declined in volume even as its value rose

According to PRODCOM production data, EU production of sulphonamides fell from approximately 8,048 tonnes (first period) to 6,734 tonnes (last period), a decline of 16.3%. However, the production value rose from €372 million to €528 million (+42%), indicating a rising unit value of domestically produced output. This is consistent with EU manufacturers concentrating on higher-value, specialised sulphonamides while ceding volume production to lower-cost producers abroad.

2. Geographic Reorientation: Switzerland as the New Import Powerhouse and the US Export Decline

The balance reversal was driven by a profound geographic restructuring on both the import and export sides. The most dramatic single change was the explosion of imports from Switzerland.

Switzerland became the dominant EU import source, growing over 700%

Switzerland's share of total EU sulphonamide imports grew from roughly 13% to over 54% in value terms. This is a remarkable concentration: by 2025, Switzerland alone accounted for more than half of all EU imports by value. This likely reflects the activities of Swiss-based pharmaceutical and chemical companies (e.g., Novartis, Roche, and specialty chemical firms) that produce or intermediate sulphonamides and route them into the EU. The proximity, regulatory alignment, and absence of tariff barriers under the EU–Switzerland bilateral agreements facilitate this trade.

South Korea also emerged as a fast-growing supplier (+654%), though from a much smaller base.

The United States remained the top export destination but with sharply diminished value

EU exports to the United States nearly halved, declining from €1.93 billion to €1.00 billion. Despite this, the US remained by far the largest single destination for EU sulphonamide exports. The decline likely reflects increased US domestic production capacity and growing competition from Asian suppliers. Meanwhile, EU exports to Switzerland (+359%), Russia (+80%), and India (+104%) grew, partially diversifying the export base.

Ireland dominated EU exports, while Slovenia emerged as a major import hub

Among EU Member States, Ireland was the leading exporter throughout the period, starting at €1.96 billion and declining to €800 million (−59.1%). Ireland's strong position is consistent with its large pharmaceutical manufacturing sector. In 2025, Ireland still accounted for roughly 48% of total EU sulphonamide exports by value and displayed an exceptionally high Revealed Comparative Advantage (RCA of 23.13, RSCA of 0.92). Germany (+254%) and Spain (+131.7%) emerged as growing exporters.

On the import side, Slovenia surged from €34 million to €2,479 million in recorded imports (+7,244%). This extraordinary increase almost certainly reflects the establishment or expansion of a major pharmaceutical manufacturing or distribution facility within Slovenia that imports large volumes of sulphonamide intermediates, likely for re-export or further processing. Germany (+70.2%) and the Netherlands (+312.1%) also saw substantial import growth.

3. Rising Vulnerability: Import Concentration, Price Shocks, and Strategic Dependence

Beyond the headline trade balance shift, several structural indicators point to a growing strategic vulnerability of the EU in sulphonamides.

Import concentration increased sharply, while export concentration eased

The Herfindahl-Hirschman Index (HHI) for imports by value rose from 1,850 (moderately concentrated) to 5,222 (highly concentrated), a 182% increase. By contrast, the export HHI fell from 6,302 to 4,087 (−35.1%), indicating that EU exports became more diversified across destination markets.

The import-side concentration was driven overwhelmingly by the growing dominance of Switzerland. At an HHI of 5,222, the EU's import structure is now considered highly concentrated, implying that any disruption to Swiss supply (regulatory changes, logistics issues, or strategic decisions by Swiss firms) could have outsized effects on EU sulphonamide availability.

By contrast, the volume-based HHI for imports remained far more stable (2,369 → 2,467), indicating that while Switzerland's share grew in value terms, the physical volumes of imports were more evenly distributed. This reflects the significantly higher unit prices of Swiss-origin imports compared to, for example, Chinese or Indian ones.

Net import reliance surged from 12% to over 72%

The EU's net import reliance rose from 12.2% in 2017 to 72.2% in 2025 — a 493% increase. In 2017, the EU was close to self-sufficient in sulphonamides; by 2025, it depended on external suppliers for nearly three-quarters of its net consumption. This metric encapsulates the combined effect of flat-to-declining export values, rising import values, and falling domestic production.

The trade intensity (total trade as a share of apparent consumption) also rose, from 99.9% to 135.9%, confirming that this market is highly globalised and that the EU's position within it has shifted from balanced participation to net absorption.

Several supply relationships exhibited high price volatility and discrete shocks

The coefficient of variation (CV) of import values reveals that several partners are unreliable in terms of year-on-year consistency:

On the export side, the most volatile destinations included Israel (CV 0.63), Switzerland (0.60), and Argentina (0.41).

Three major price shock events were detected:

The 2022 export price shock to Japan (with an abnormality score of 21.0, the highest detected) likely reflects post-pandemic supply chain repricing or a shift in product mix. The 2019 US import price shock (+109%) affected a quarter of import value at the time and may reflect tariff-related disruptions or shifts in sourcing patterns.

Conclusion

Over the period 2017–2025, the EU's sulphonamide market (CN 29359090) underwent a fundamental transformation. The bloc shifted from a net exporter with a €715 million surplus to a net importer running a €1.9 billion deficit, as import values doubled while export values fell by a third. This was driven by two interlinked dynamics: a surge in high-value imports — predominantly from Switzerland, which grew to account for over half of import value — and a decline in domestic production volumes, even as Ireland remained the EU's largest exporter. The import side became significantly more concentrated (HHI rising from 1,850 to 5,222), and net import reliance climbed from 12% to 72%, raising strategic concerns about EU dependence on a small number of external suppliers. While EU export markets diversified somewhat, the overall trajectory points to a loss of competitive position in sulphonamide manufacturing, with the EU increasingly serving as an import platform for pharmaceutical intermediates rather than a self-sufficient producer. These dynamics merit close monitoring from an industrial policy and supply-chain security perspective.